BRAIN Biotech AG Net Assets
BRAIN Biotech AG net assets. Based on the latest financial reports, BRAIN Biotech AG (BNN) has net assets worth €1.84 Million EUR (≈ $2.15 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€66.34 Million ≈ $77.55 Million USD) and total liabilities (€64.50 Million ≈ $75.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BRAIN Biotech AG equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.84 Million |
| % of Total Assets | 2.78% |
| Annual Growth Rate | -13.5% |
| 5-Year Change | -95.6% |
| 10-Year Change | -93.16% |
| Growth Volatility | 111.52 |
Net Assets of BRAIN Biotech AG (2012–2025)
Net assets of BRAIN Biotech AG from 2012 to 2025. This chart illustrates how BRAIN Biotech AG's net assets have evolved over time, based on quarterly financial data. See BRAIN Biotech AG (BNN) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for BRAIN Biotech AG (2012–2025)
The table below shows the annual net assets of BRAIN Biotech AG from 2012 to 2025. For live market cap and overall valuation, see how much is BRAIN Biotech AG worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | €1.84 Million ≈ $2.15 Million |
-86.74% |
| 2024-09-30 | €13.89 Million ≈ $16.23 Million |
-39.66% |
| 2023-09-30 | €23.01 Million ≈ $26.91 Million |
-32.80% |
| 2022-09-30 | €34.25 Million ≈ $40.04 Million |
-18.12% |
| 2021-09-30 | €41.83 Million ≈ $48.90 Million |
+59.99% |
| 2020-09-30 | €26.14 Million ≈ $30.56 Million |
+52.96% |
| 2019-09-30 | €17.09 Million ≈ $19.98 Million |
-44.22% |
| 2018-09-30 | €30.64 Million ≈ $35.82 Million |
-35.31% |
| 2017-09-30 | €47.36 Million ≈ $55.37 Million |
+75.90% |
| 2016-09-30 | €26.93 Million ≈ $31.48 Million |
+367.85% |
| 2015-09-30 | €5.76 Million ≈ $6.73 Million |
-58.44% |
| 2014-09-30 | €13.85 Million ≈ $16.19 Million |
-21.28% |
| 2013-09-30 | €17.59 Million ≈ $20.57 Million |
+45.10% |
| 2012-09-30 | €12.12 Million ≈ $14.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BRAIN Biotech AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10782043100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
BRAIN Biotech AG Net Assets Breakdown (September 2025)
BRAIN Biotech AG net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €21.85 Million | 1186.69% |
| Other Comprehensive Income | €295.00K | 16.02% |
| Other Components | €95.73 Million | 5200.05% |
| Total Equity | €1.84 Million | 100.00% |
BRAIN Biotech AG Competitors by Market Cap
The table below lists competitors of BRAIN Biotech AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JR Invest SA
WAR:JRH
|
$51.56 Million |
|
Futuretech II Acquisition Corp
NASDAQ:FTII
|
$51.57 Million |
|
Gogoro Inc
NASDAQ:GGR
|
$51.59 Million |
|
Vbt Yazilim AS
IS:VBTYZ
|
$51.62 Million |
|
Stefstock
JSE:SSK
|
$51.55 Million |
|
Lida Holdings Ltd
TW:4552
|
$51.53 Million |
|
Dsr Wire
KO:069730
|
$51.53 Million |
|
iBio, Inc. Common Stock
NASDAQ:IBIO
|
$51.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BRAIN Biotech AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,617,000 to 1,841,000, a change of -10,776,000 (-85.4%).
- Net loss of 11,742,000 reduced equity.
- Other comprehensive income decreased equity by 1,018,000.
- Other factors increased equity by 1,984,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-11.74 Million | -637.81% |
| Other Comprehensive Income | €-1.02 Million | -55.3% |
| Other Changes | €1.98 Million | +107.77% |
| Total Change | €- | -85.41% |
Book Value vs Market Value Analysis
This analysis compares BRAIN Biotech AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 31.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.66x to 31.45x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-09-30 | €1.00 | €2.65 | x |
| 2013-09-30 | €1.48 | €2.65 | x |
| 2014-09-30 | €0.96 | €2.65 | x |
| 2015-09-30 | €0.43 | €2.65 | x |
| 2016-09-30 | €1.76 | €2.65 | x |
| 2017-09-30 | €2.86 | €2.65 | x |
| 2018-09-30 | €1.43 | €2.65 | x |
| 2019-09-30 | €0.68 | €2.65 | x |
| 2020-09-30 | €1.11 | €2.65 | x |
| 2021-09-30 | €1.94 | €2.65 | x |
| 2022-09-30 | €1.36 | €2.65 | x |
| 2023-09-30 | €1.00 | €2.65 | x |
| 2024-09-30 | €0.58 | €2.65 | x |
| 2025-09-30 | €0.08 | €2.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BRAIN Biotech AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -637.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23.66%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 36.03x
- Recent ROE (-637.81%) is below the historical average (-89.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -48.53% | -74.06% | 0.38x | 1.73x | €-6.68 Million |
| 2013 | -23.67% | -40.41% | 0.40x | 1.45x | €-5.83 Million |
| 2014 | -41.16% | -38.84% | 0.52x | 2.05x | €-6.27 Million |
| 2015 | -104.84% | -27.04% | 0.69x | 5.58x | €-6.26 Million |
| 2016 | -55.06% | -64.46% | 0.48x | 1.78x | €-17.36 Million |
| 2017 | -20.36% | -39.85% | 0.35x | 1.45x | €-14.32 Million |
| 2018 | -32.13% | -30.59% | 0.36x | 2.89x | €-10.85 Million |
| 2019 | -85.79% | -27.22% | 0.58x | 5.40x | €-11.72 Million |
| 2020 | -46.59% | -25.33% | 0.53x | 3.47x | €-11.76 Million |
| 2021 | -12.82% | -12.95% | 0.49x | 2.00x | €-8.85 Million |
| 2022 | -22.23% | -13.31% | 0.63x | 2.63x | €-9.55 Million |
| 2023 | -38.03% | -14.96% | 0.78x | 3.26x | €-10.46 Million |
| 2024 | -88.19% | -20.37% | 0.62x | 7.03x | €-12.39 Million |
| 2025 | -637.81% | -23.66% | 0.75x | 36.03x | €-11.93 Million |
Industry Comparison
This section compares BRAIN Biotech AG's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $739,305,598
- Average return on equity (ROE) among peers: -11.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BRAIN Biotech AG (BNN) | €1.84 Million | -48.53% | 35.03x | $51.56 Million |
| LIFELINE SPAC I OYJ A EO1 (0CD) | $113.50 Million | -3.17% | 0.10x | $179.00 Million |
| GRAPHENE MANUFACT.GROUP (0GF) | $2.03 Million | 0.00% | 1.43x | $171.50 Million |
| Orion Engineered Carbons SA (0OE) | $181.01 Million | 10.03% | 6.68x | $319.07 Million |
| COVESTRO AG SP.ADR 1/2 (1CO1) | $6.68 Billion | -3.98% | 1.04x | $11.11 Billion |
| H&R GmbH & Co. KGaA (2HRA) | $164.58 Million | 31.60% | 1.42x | $183.88 Million |
| LOOP INDUSTRIES DL-001 (3L9) | $33.74 Million | -63.14% | 0.20x | $13.35 Million |
| Dotz Nano Ltd (57N) | $-244.59K | 0.00% | 0.00x | $4.51 Million |
| TIDEWATER RENEWABLES LTD (7GZ) | $155.20 Million | 2.26% | 1.56x | $409.20 Million |
| DIRECTA PLUS PLC LS-0025 (88K) | $10.83 Million | -44.54% | 0.53x | $2.35 Million |
| TEKNA HOLDING ASA NK 2 (8VB) | $53.41 Million | -40.60% | 0.38x | $67.10 Million |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more